Genetic and lifestyle factors are independently associated with incident stroke among men and women aged 40 to 73 years.
Olaparib maintenance therapy after platinum chemotherapy substantially prolonged PFS compared with placebo in newly diagnosed advanced ovarian cancer.
Talzenna, a poly (ADP-ribose) polymerase (PARP) inhibitor, was evaluated in EMBRACA, an open-label trial that randomized patients with gBRCAm HER2-negative locally advanced or metastatic breast cancer (N=431) to receive talazoparib 1mg or physician's choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine).
Assay can be used to determine blood donor and patient non-ABO red blood cell types.
82 percent of variant carriers identified in exome sequencing had not undergone prior testing.
A case and commentary published in the AMA Journal of Ethics discusses the ethics of primary care physician response to direct-to-consumer genetic testing results of concerned patients.
Talazoparib, a poly(adenosine diphosphate-ribose) inhibitor, may significantly enhance progression-free survival in patients with advanced breast cancer and a germline BRCA1/2 mutation.
The FDA based its approval on the results of a triplet of phase 3 studies, the MONALEESA-2, MONALEESA-3, and MONALEESA-7.
For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.
Three factors help identify absolute 10-year risk of Alzheimer's disease, all dementia for different groups.
Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.
Expression of KLRD1 by natural killer cells before infection associated with influenza severity.
Before the Affordable Care Act, insurance companies could deny coverage to patients based on genetic testing results.
For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.
Reduced interest seen in minority and less educated populations.
Ethical discussion relates to issues of informed consent, privacy, and justice
The genetic risk score primarily modified the risk for and onset of dementia and AD among homozygous carriers for APOE ε4.
In 2003, the Human Genome Project became the culmination of the history of genetics research, allowing us to understand the role of genetics in human health and disease. As part of The Clinical Advisor's 20th Anniversary, this article explores the influence of race and genetics in clinical practice.
Complete genome sequences were elucidated for 31 fetuses from amniotic fluid. Two methods of DNA extraction proved to be relatively equal in quality of complete genome sequence.
The disease allele may be passed from affected grandmother to granddaughter through the father's inherited genes.
Understanding genetic testing allows providers to make the most of this resource in patient care.
The test will provide information on an individual's genetic predisposition to 10 diseases or conditions.
Published practice bulletins offer guidance to clinicians on patient education during pregnancy.
Primary care clinicians should be proficient at assessing the potential for hereditary breast cancer risk in their patients.
Women who receive genetic counseling prior to undergoing BRCA testing display more knowledge of both the testing process and of the potential results.
For hereditary breast, ovarian cancer, multigene testing can influence clinical treatment options.
The activity of a gene called vanin-1 (VNN1) affected whether they were good or poor responders to corticosteroid treatment.
In the absence of Mbd2, dendritic cells display reduced phenotypic activation and a markedly impaired capacity to initiate immunity against helminthes or allergens.
There is a relative 13.5% increase in coronary artery disease risk for every 2.5 inches shaved off a person's height.
The Food and Drug Administration (FDA) has granted marketing of the EnLite Neonatal TREC Kit, the first FDA-cleared test to screen for severe combined immunodeficiency (SCID) in newborns.